Bengaluru-based OneSource Specialty Pharma (formerly known as Stelis Biopharma), associate company of Strides and India’s first specialty pharma pure-play Contract Development and Manufacturing Organisation (CDMO) has entered into a strategic licensing agreement with Bhami’s Research Laboratory (BRL).

This partnership will provide OneSource with access to BRL’s HILOPRO^Ò formulation technology, enabling the subcutaneous delivery of high-concentration biologic therapies. 

This innovative technology aims to reduce viscosity and facilitate the delivery of high-concentration biologic products, applicable across a broad spectrum of monoclonal antibodies and fusion proteins. Under the agreement, OneSource will offer BRL’s innovative formulation technology, enhancing its development and manufacturing services for both drug products and substances.

OneSource offers world-class capabilities across biologics, complex injectables and drug-device combination products, soft gelatin capsules and has demonstrated experience on different therapeutic modalities and technology platforms. With five state-of-the-art cGMP facilities and a global customer base, OneSource has an impeccable quality compliance record with successful inspections by major health agencies, including the US FDA and EU authorities.